Physician profile
Luis Eraso
NPI 1366487340
$451.41
in general payments reported to CMS, 2019-2025
11 companies · $94.26 in 2025
The $94.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.82 · 2020: $66.69 · 2021: $14.84 · 2023: $86.67 · 2024: $124 · 2025: $94.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $107.34 | 2024-2025 | |
| Smith+Nephew, INC. | $102.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $86.65 | 2023-2024 | Xarelto |
| Organogenesis INC. | $24.13 | 2019 | |
| Reddress USA, INC. | $23.78 | 2023 | |
| Kci USA, INC. | $21.08 | 2023 | Activ.A.C. |
| Teleflex LLC | $20.98 | 2024 | Solesta |
| Osiris Therapeutics INC. | $19.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $14.74 | 2024 | Eliquis |
| Boston Scientific Corporation | $14.25 | 2024 | Eluvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Eraso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.